According to epidemiological studies, the prevalence of systemic autoimmune diseases (SADs) is increasing annually, and the leading positions in the pediatric nosological structure are consistently occupied by juvenile idiopathic arthritis, systemic lupus erythematosus, and juvenile dermatomyositis. Despite the introduction of biological and targeted disease-modifying therapies, chronic inflammation and the risk of infectious complications remain a pressing problem, which necessitates the search for new pathogenetically based approaches, in particular those related to the mechanisms of immunosenescence. Aim - to assess the impact of cellular senescence on the development of juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE), to determine its clinical significance in terms of the activity of the pathological process, resistance to therapy, and prognosis of the disease course. Narrative literature review with elements of systematic search according to PRISMA 2020 recommendations. Proinflammatory cytokines (IL-1β, IL-6, TNF-α) are the main triggers of senescence of immunocytes and tissue cells. In JIA, the process is predominantly local in nature (synovia). Senescent fibroblasts and T-cells produce TNF-α, IL-6, matrix metalloproteinases, which leads to joint damage. In SLE, senescence is systemic. Premature aging is observed in immunocytes, including B cells, podocytes, endothelium, and microglia, which is analyzed in the development of lupus nephritis and CNS damage. Senescence markers (p16INK4a, p21CIP1, SA-β-gal, telomere shortening) are promising biomarkers of activity and prognosis of autoimmune diseases. Conclusions. Cellular senescence is an important factor accompanying the adverse course of JIA and SLE. A promising direction for maintaining remission may be the use of senolytics and senomodifiers. Further pediatric studies are needed to validate biomarkers and therapeutic targets. The authors declare no conflict of interest.